Noroviruses and histo-blood groups: The impact of common host genetic polymorphisms on virus transmission and evolution

Reviews in Medical Virology

Volumn 23, Issue 6, 2013, Pages 355-366

  Ruvoën Clouet, Nathalie ^a,b   Belliot, Gaël ^c   Le Pendu, Jacques ^b  

^a LUNAM UNIVERSITÉ   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FUCOSYLTRANSFERASE 2; FUCOSYLTRANSFERASE 3; GLYCOSYLTRANSFERASE; HISTO BLOOD GROUP ABO SYSTEM TRANSFERASE; NEUTRALIZING ANTIBODY; PROTEIN VP1; PROTEIN VP2; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ANTIGEN BINDING; BINDING SITE; BLOOD GROUP LEWIS SYSTEM; EPIDEMIOLOGY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HERD IMMUNITY; HEREDITY; HUMAN; IN VITRO STUDY; INFECTION RESISTANCE; INNATE IMMUNITY; MOLECULAR EVOLUTION; MUTAGENESIS; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PHYLOGENETIC TREE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS STRAIN; VIRUS TRANSMISSION;

BLOOD GROUP ANTIGENS; CALICIVIRIDAE INFECTIONS; DISEASE SUSCEPTIBILITY; HISTOCOMPATIBILITY ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; NOROVIRUS; POLYMORPHISM, GENETIC; RECEPTORS, VIRUS; VIRUS ATTACHMENT;

EID: 84887160975     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1757     Document Type: Review

References (66)

1. Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. Journal of Infectious Diseases 2009; 200: 802-812.
2. Kroneman A, Verhoef L, Harris J, et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the foodborne viruses in Europe network from 1 July 2001 to 30 June 2006. Journal of Clinical Microbiology 2008; 46: 2959-2965. DOI: JCM.00499-08[pii]10.1128/JCM.00499-08
3. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States-unspecified agents. Emerging Infectious Diseases 2011; 17: 16-22.
4. Phillips G, Tam CC, Conti S, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. American Journal of Epidemiology 2010; 171: 1014-1022.
5. Patel MN, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of the role of noroviruses in sporadic gastroenteritis. Emerging Infectious Diseases 2008; 14: 1224-1231.
6. Hall A Noroviruses: the perfect human pathogens? Journal of Infectious Diseases 2012; 205: 1622-1626. DOI: 10.1093/infdis/jis251
7. Gustavsson L, Andersson LM, Lindh M, Westin J. Excess mortality following community-onset norovirus enteritis in the elderly. Journal of Hospital Infection 2011; 79: 27-31.
8. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. New England Journal of Medicine 2012; 367: 2126-2132.
9. Trivedi TK, Desai R, Hall AJ, et al. Clinical characteristics of norovirus-associated deaths: a systematic literature review. American Journal of Infection Control 2013; 41(7): 654-657.
10. Le Guyader FS, Atmar RL, Le Pendu J. Transmission of viruses through shellfish: when specific ligands come into play. Current Optical Virology 2012; 2: 103-110.
11. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. New England Journal of Medicine 2009; 361: 1776-1785.
12. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006; 346: 312-323.
13. Mesquita JR, Barclay L, Nascimento MS, Vinje J. Novel norovirus in dogs with diarrhea. Emerging Infectious Diseases 2010; 16: 980-982.
14. Hall AJ, Vinjé J, Lopman B, et al. Center for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR 2011; 60: 1-15.
15. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. Journal of Clinical Virology 2009; 44: 1-8.
16. Bok K, Abente EJ, Realpe-Quintero M, et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. Journal of Virology 2009; 83: 11890-11901.
17. Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clinical Infectious Diseases 2012; 55: 189-193.
18. Ruvoën-clouet N, Ganière JP, André-Fontaine G, Blanchard D, Le Pendu J. Binding of rabbit hemorrhagic disease virus to antigens of the ABH histo-blood group family. Journal of Virology 2000; 74: 11950-11954.
19. Marionneau S, Cailleau-Thomas A, Rocher J, et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 2001; 83: 565-573.
20. Le Pendu J, Ruvöen-Clouet N, Kindberg E, Svensson L. Mendelian resistance to human norovirus infections. Seminars Immunology 2006; 18: 375-386.
21. Hutson AM, Airaud F, Le Pendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. Journal of Medical Virology 2005; 77: 116-120.
22. Lindesmith L, Moe CL, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nature Medicine 2003; 9: 548-553.
23. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000; 108: 1-28.
24. Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends in Microbiology 2011; 19: 382-388.
25. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerging Infectious Diseases 2010; 16: 81-87.
26. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 norovirus infection. PLoS One 2009; 4: e5593.
27. Rockx BH, Vennema H, Hoebe CJ, Duizer E, Koopmans M. Association of histo-blood group antigens and susceptibility to norovirus infections. Journal of Infectious Diseases 2005; 191: 749-754.
28. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. Journal of Infectious Diseases 2012; 206: 1386-1393.
29. Meyer E, Ebner W, Scholz R, Dettenkoffer M, Daschner FD. Nosocomial outbreak of norovirus gastroenteritis and investigation of ABO histo-blood group type in infected staff and patients. Journal of Hospital Infection 2004; 56: 64-66.
30. Miyoshi M, Yoshizumi S, Sato C, Okui T, Ogawa H, Honma H. Relationship between ABO histo-blood group type and an outbreak of norovirus gastroenteritis among primary and junior high school students: results of questionnaire-based study. Kansenshōgaku Zasshi 2005; 79: 664-671.
31. Fretz R, Svoboda P, Schorr D, Tanner M, Baumgartner A. Risk factors for infections with norovirus gastrointestinal illness in Switzerland. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24: 256-261.
32. Halperin T, Vennema H, Koopmans M, et al. No association between histo-blood group antigens and susceptibility to clinical infections with genogroup II norovirus. Journal of Infectious Diseases 2008; 197: 63-65.
33. Larsson MM, Rydell GE, Grahn A, et al. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. Journal of Infectious Diseases 2006; 194: 1422-1427.
34. Bok K, Parra GI, Mitra T, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proceedings of the National Academy of Sciences 2011; 108: 325-330.
35. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. Journal of Infectious Diseases 2010; 202: 1212-1218.
36. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clinical and Vaccine Immunology 2012; 19: 284-287.
37. Tan M, Hedge RS, Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. Journal of Virology 2004; 78: 6233-6242.
38. Bu W, Mamedova A, Tan M, Xia M, Jiang X, Hegde RS. Structural basis for the receptor binding specificity of Norwalk virus. Journal of Virology 2008; 82: 5340-5347.
39. Choi J-M, Hutson AM, Estes MK, Prasad BV. Atomic resolution structural characterisation of recognition of histo-blood group antigens by Norwalk virus. Proceedings of the National Academy of Sciences 2008; 105: 9175-9180.
40. Tan M, Xia M, Chen Y, et al. Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS One 2009; 4: e5058.
41. Cao S, Lou Z, Tan M, et al. Structural basis for the recognition of blood group trisaccharides by norovirus. Journal of Virology 2007; 81: 5949-5957.
42. Tan M, Xia M, Cao S, et al. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 2008; 379: 324-334.
43. de Rougemont A, Ruvoën-Clouet N, Simon B, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. Journal of Virology 2011; 85: 4057-4070.
44. Hansman G, Biertumpfel C, Georgiev I, et al. Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. Journal of Virology 2011; 85: 6687-7388.
45. Chen Y, Tan M, Xia M, et al. Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathogens 2011; 7: e1002152.
46. Shirato H, Ogawa S, Ito H, et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. Journal of Virology 2008; 82: 10756-10767.
47. Kubota T, Kumagai A, Ito H, et al. Structural basis for the recognition of Lewis antigens by genogroup I norovirus. Journal of Virology 2012; 86: 11138-11150.
48. Lindesmith L, Donaldson EF, Lobue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Medicine 2008; 5: e31.
49. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. Journal of Infectious Diseases 1990; 161: 18-21.
50. Dolin R, Blacklow NR, DuPont H, et al. Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. Journal of Infectious Diseases 1971; 123: 307-312.
51. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. New England Journal of Medicine 1977; 297: 86-89.
52. Donaldson EF, Lindesmith L, LoBue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nature Reviews Microbiology 2010; 8: 231-240.
53. Lindesmith LC, Donaldson E, Leon J, et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. Journal of Virology 2010; 84: 1800-1815.
54. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends in Microbiology 2011; 19: 233-240.
55. Siebenga JJ, Vennema H, Renckens B, et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. Journal of Virology 2007; 81: 9932-9941.
56. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathogens 2010; 6: e1000831.
57. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 2008; 3: e1485.
58. Debbink K, Donaldson E, Lindesmith L, Baric R. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. Journal of Virology 2012; 86: 1214-1240.
59. Lindesmith LC, Costantini V, Swanstrom J, et al. Norovirus GII.4 strain emergence correlates with changes in evolving blockade epitopes. Journal of Virology 2012. DOI: JVI.03106-12 [pii] 10.1128/JVI.03106-12
60. Parra GI, Abente EJ, Sandoval-Jaime C, Sosnovtsev SV, Bok K, Green KY. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. Journal of Virology 2012; 86: 7414-7426.
61. Zakikhany K, Allen DJ, Brown D, Iturriza-Gomara M. Molecular evolution of GII-4 norovirus strains. PLoS One 2012; 7: e41625.
62. Yang Y, Xia M, Tan M, et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. Journal of Virology 2010; 84: 9595-9607.
63. Boon D, Mahar JE, Abente EJ, et al. Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. Journal of Virology 2011; 85: 8656-8666.
64. Anderson RM. Discussion: the Kermack-McKendrick epidemic threshold theorem. Bulletin of Mathematical Biology 1991; 53: 3-32.
65. Matrajt L, Longini IM, Jr. Critical immune and vaccination thresholds for determining multiple influenza epidemic waves. Epidemics 2012; 4: 22-32.
66. Rydell GE, Nilsson J, Rodriguez-Diaz J, et al. Human noroviruses recognize sialyl-Lewis x neoglycoprotein. Glycobiology 2009; 19: 309-320.